ROACTEMRA (tocilizumab), interleukin 6 receptor inhibitor

RHEUMATOLOGY - New indication

Opinions on drugs - Posted on Mar 24 2016

Inclusion

ROACTEMRA, in combination with methotrexate (MTX), now has Marketing Authorisation in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. In addition, it can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.
In combination with MTX, it reduces the rate of progression of joint damage as measured by X-ray and improves physical function.
It is preferable to give patients MTX as first-line therapy, with a treatment adjustment strategy that includes introducing a biopharmaceutical where applicable (after failure of MTX).
ROACTEMRA has no role in the treatment strategy for patients who have not been previously treated with a conventional disease-modifying drug, in particular MTX.

Insufficient

Évaluation des médicaments

All our publications

My account